Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by 10x Genomics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: 10x Genomics, Inc.’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 6, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-054491
FAQ
- What is 10x Genomics, Inc.'s D&A?
- 10x Genomics, Inc. (TXG) reported D&A of $9.66M in Q2 2026.
- How has 10x Genomics, Inc.'s D&A changed year-over-year?
- 10x Genomics, Inc.'s D&A increased by 23.7% year-over-year, from $7.82M to $9.66M.
- What is the long-term trend for 10x Genomics, Inc.'s D&A?
- Over 4 years (2021 to 2025), 10x Genomics, Inc.'s D&A has grown at a 14.4% compound annual growth rate (CAGR), from $21.12M to $36.2M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about 10x Genomics, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude